新型コロナウイルス感染症（COVID-19）パイプライン医薬品：機会評価、疫学研究、 市場力学 、パイプライン分析H1 （2020年）
Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020
|発行||GervanoRA Data Services LLP||商品コード||940538|
|出版日||ページ情報||英文 255 Pages
|新型コロナウイルス感染症（COVID-19）パイプライン医薬品：機会評価、疫学研究、 市場力学 、パイプライン分析H1 （2020年） Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020|
|出版日: 2020年06月06日||ページ情報: 英文 255 Pages||
GervanoRA's pipeline analysis and opportunity assessment report "Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020" analysed and assessed Coronavirus Disease 2019 (COVID-19) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 therapeutics industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the COVID-19 disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 drugs and vaccines industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of COVID-19.
Our comprehensive analysis on the COVID-19 therapeutic pipeline identified 322 therapeutic candidates (drugs and vaccines) undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, 146 therapeutics are in clinical stages of development and a total of 161 molecules are in non-clinical stage of development. The drug pipeline consists of 151 preclinical drug candidates and 10 molecules still in their early stages of discovery.
The report has covered more than 310 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.